ABS Takes Smart Class Services Mobile
ABS today launches a unique suite of fleet management and vessel compliance services powered by smart functionality and advanced analytics which, in an industry first, will also be available through the new ABS App.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200720005501/en/
ABS MyFreedom - Now It All Clicks (Graphic: Business Wire)
Designed to anticipate client needs and provide intuitive, informed decision support, the smart functionality is an enhancement to the ABS MyFreedom™ client portal and can be accessed through a mobile app or text. The portal and the industry’s most user-friendly digital tools simplify access to operational, technical and compliance fleet intelligence and all ABS Class services to manage the operating health and performance of fleets.
New industry-leading smart functionality launched today includes:
- The ABS Smart Scheduler™ , which leverages real-time AIS data to maintain fleet compliance and is the industry’s only mobile survey booking tool enabling any survey, including remote surveys, to be scheduled in less than a minute anytime, anywhere – even when there is no internet access. It tracks survey status for all vessels in a fleet and then issues alerts when surveys are due.
- Custom Checklist, which brings together port state data from all ABS-classed vessels to provide a port-specific checklist for crew and fleet managers prior to arrival at any port.
- Fee Estimator, which provides a comparison of estimated survey fees across multiple ports.
- Port State Control Risk, which provides customized port state control analytics by vessel or fleet. It allows clients to view their destination’s top deficiency items and the client vessel’s matching findings from ABS class records, along with a vessel risk rating based on compliance health status.
- International Safety Management (ISM) Findings, customized to individual vessel performance, which allows clients to view the destination port’s top ISM related deficiency items against their vessel’s matching findings from ABS class records.
- Port-Specific External Specialists, which provides one-touch direct client connections for upcoming surveys.
“Leveraging unprecedented access to data, we are delivering truly smart functionality that learns from the user and, with experience over time, anticipates future requirements, making it even easier to work with ABS,” said Christopher J. Wiernicki, ABS Chairman, President and CEO. “These are just the first of many enhancements and increased smart functionality that ABS will continue to deliver through the MyFreedom client portal. The portal brings together all of our clients’ Class needs digitally for a complete overview, so now it all clicks. Centralized and connected, it streamlines interactions with ABS, making our client experience straightforward and insightful.”
Offering enhanced risk management, compliance and operational efficiency through better informed decision making, MyFreedom delivers total fleet oversight, real-time survey status, smart scheduling, remote survey options, including annual surveys with mobile capture and collaboration, simplified access to compliance data and timely fleet certification renewals.
Visit our website for more information.
The ABS App is now available from the Apple App Store and Google Play.
▬▬
About ABS
ABS, a leading global provider of classification and technical advisory services to the marine and offshore industries, is committed to setting standards for safety and excellence in design and construction. Focused on safe and practical application of advanced technologies and digital solutions, ABS works with industry and clients to develop accurate and cost-effective compliance, optimized performance and operational efficiency for marine and offshore assets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005501/en/
Contact information
Gareth Lewis
ABS
Global Media Relations Manager
Tel: +44 (0)20 7377 4514
Mob: +44 (0)7824 374395
Email: glewis@eagle.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
